Metastatic Osteosarcoma Clinical Trial
Official title:
Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma
The primary goal of this study will be to examine tumor response after radiation treatment via a combination of Samarium-153 EDTMP and external beam radiotherapy.
Samarium tracer infusion of 1 mCi/kg administered. SPECT images wil be used to determine the distribution of dose delivered to the tumor. This information will be used to determine target doses of external beam radiotherapy. The treatment infusion of Samarium, 30 mCi/kg, will be administered and dosimetry will confirm total dose delivered, and information will be used to finalize doses of external beam radiotherapy. Approximately 14 days after treatment infusion, autologous stem cells infusion is administered. Radiotherapy will be delivered according to the judgement of the treating radiation oncologist. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00093821 -
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
|
Phase 1 | |
| Completed |
NCT01553539 -
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
| Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
| Recruiting |
NCT04668300 -
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
|
Phase 2 | |
| Completed |
NCT02470091 -
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
|
Phase 2 | |
| Completed |
NCT01807052 -
Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas
|
N/A | |
| Completed |
NCT01016015 -
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
|
Phase 2 | |
| Completed |
NCT00134030 -
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
|
Phase 3 | |
| Suspended |
NCT05691478 -
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
|
Phase 2/Phase 3 | |
| Completed |
NCT02357810 -
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
|
Phase 2 | |
| Active, not recruiting |
NCT01590069 -
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
|
Phase 1 | |
| Completed |
NCT01804374 -
Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma
|
Phase 2 | |
| Completed |
NCT01154452 -
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00330421 -
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
|
Phase 2 | |
| Completed |
NCT01374672 -
Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma
|
N/A | |
| Completed |
NCT00023998 -
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
|
Phase 2 | |
| Completed |
NCT00954473 -
Study of Blood Samples From Patients With Osteosarcoma
|
N/A | |
| Completed |
NCT02484443 -
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT05683197 -
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT02243605 -
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
|
Phase 2 |